1. Home
  2. Browse
  3. HRA003549
HRA003549
   HRA003549.xlsx
Title:
Afatinib as Neoadjuvant Treatment for Stage III EGFR-Mutant Non-Small Cell Lung Cancer
Release date:
2023-07-09
Description:
The single-arm, phase II trial was registered with ClinicalTrial.gov (NCT04201756) and conducted in Shanghai Pulmonary Hospital. Between July 2020 and February 2022, patients with stage III NSCLC with EGFR mutations were enrolled. Patients received neoadjuvant treatment with Afatinib (40mg once daily for 8 to 16 weeks) and were reassessed every 4 weeks for feasibility of radical resection. The primary endpoint was objective response rate.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA013411
Study type:
Disease Study
Disease name:
non-small cell lung carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC002005
DAC name:
Targeted therapy of NSCLC
Contact person:
Zhang Peng
Email:
zhangpeng1121@tongji.edu.cn
Description:
Targeted therapy has improved the treatment non-small cell lung cancer (NSCLC) with driver gene mutations. However, most patients will develop drug resistance after therapy. Here, we combined bulk, single cell and spatial transcriptomics to identify the spatial landscape of the NSCLC tumor microenvironment (TME) during targeted therapy. Multidimensional bioinformatics analyses revealed distinct transcriptomic heterogeneity of the TME. Our study provides novel insights into the complex ecosystem of NSCLC and offers clues for combinational therapies to overcome drug resistance.
Individuals & samples
Files
Request Data
Submitter:   Zhang Peng / zhangpeng1121@tongji.edu.cn
Organization:   Shanghai Pulmonary Hospital Tongji University
Submission date:   2022-11-22
Requests:   5